Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Non-Current Liabilities: 2020-2022

Historic Total Non-Current Liabilities for Candel Therapeutics (CADL) over the last 3 years, with Dec 2022 value amounting to $28.1 million.

  • Candel Therapeutics' Total Non-Current Liabilities fell 5.83% to $26.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.6 million, marking a year-over-year decrease of 5.83%. This contributed to the annual value of $28.1 million for FY2022, which is 312.19% up from last year.
  • As of FY2022, Candel Therapeutics' Total Non-Current Liabilities stood at $28.1 million, which was up 312.19% from $6.8 million recorded in FY2021.
  • Candel Therapeutics' Total Non-Current Liabilities' 5-year high stood at $28.1 million during FY2022, with a 5-year trough of $6.0 million in FY2020.
  • In the last 3 years, Candel Therapeutics' Total Non-Current Liabilities had a median value of $6.8 million in 2021 and averaged $13.6 million.
  • Data for Candel Therapeutics' Total Non-Current Liabilities shows a peak YoY surged of 312.19% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows Candel Therapeutics' Total Non-Current Liabilities stood at $6.0 million in 2020, then increased by 14.50% to $6.8 million in 2021, then spiked by 312.19% to $28.1 million in 2022.